查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
胆囊炎治疗的全球市场(2022年～2029年)
市场调查报告书
商品编码
1093804

胆囊炎治疗的全球市场(2022年～2029年)

Global Cholecystitis Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 189 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

本报告提供全球胆囊炎治疗市场相关调查分析，提供市场动态，产业分析，市场分析，竞争情形等系统性资讯。

目录

第1章 全球胆囊炎治疗市场调查手法和范围

  • 调查手法
  • 调查的目的和调查范围

第2章 全球胆囊炎治疗市场-市场定义和概要

第3章 全球胆囊炎治疗市场-摘要整理

  • 市场明细:各原因
  • 市场明细:不同治疗
  • 市场明细:各终端用户
  • 市场明细:各地区

第4章 全球胆囊炎治疗市场-市场动态

  • 影响市场的要素
    • 促进因素
    • 阻碍因素
    • 市场机会
    • 影响分析

第5章 全球胆囊炎治疗市场-产业分析

  • 波特的五力分析
  • 供应链分析
  • 法规分析

第6章 全球胆囊炎治疗市场上COVID-19分析

  • 市场COVID-19分析
    • COVID-19前的市场方案
    • 目前COVID-19市场方案
    • COVID-19后的市场方案/未来市场方案
  • COVID-19价格的动态
  • 需求与供给的频谱
  • 政府在COVID-19疫情下的市场相关措施
  • 製造商策略性举措
  • 结论

第7章 全球胆囊炎治疗市场:各原因

  • 简介
    • 市场规模分析，及与前一年同期比较成长分析(%):各原因
    • 市场魅力指数:各原因
  • 胆囊结石*
    • 简介
    • 市场规模分析，100万美元(2020年～2029年)，及与前一年同期比较成长分析(%)(2021年～2029年)
  • 肿瘤
  • 胆管闭塞
  • 微生物感染疾病
  • 其他

第8章 全球胆囊炎治疗市场:不同治疗

  • 简介
    • 市场规模分析，及与前一年同期比较成长分析(%):不同治疗
    • 市场魅力指数:不同治疗
  • 投药*
    • 简介
    • 市场规模分析，100万美元(2020年～2029年)，及与前一年同期比较成长分析(%)(2021年～2029年)
  • ERCP(经内视镜逆行性胆胰管摄影术)

第9章 全球胆囊炎治疗市场:各终端用户

  • 简介
    • 市场规模分析，及与前一年同期比较成长分析(%):各终端用户
    • 市场魅力指数:各终端用户
  • 医院*
    • 简介
    • 市场规模分析，100万美元(2020年～2029年)，及与前一年同期比较成长分析(%)(2021年～2029年)
  • 妇产科诊所
  • 门诊病人手术中心
  • 其他

第10章 全球胆囊炎治疗市场:各地区

  • 简介
    • 市场规模分析，100万美元(2020年～2029年)，及与前一年同期比较成长分析(%)(2021年～2029年):各地区
    • 市场魅力指数:各地区
  • 北美
  • 欧洲
  • 南美
  • 亚太地区
  • 中东和非洲

第11章 全球胆囊炎治疗市场-竞争情形

  • 主要的开发与策略
  • 企业占有率分析
  • 产品的基准

第12章 全球胆囊炎治疗市场-企业简介概要

  • Fresenius Kabi*
    • 企业概要
    • 产品系列及说明
    • 主要亮点
    • 财务概要
  • Dornier MedTech GmbH
  • AuroMedics Pharmaceuticals
  • Sanofi
  • Sunuet Pharmaceuticals
  • Hetero Healthcare
  • Novartis
  • Gilead Sciences Inc
  • Takeda Pharmaceuticals
  • Boston Scientific Corporation

第13章 全球胆囊炎治疗市场-DataM

  • 附录
  • 关于本公司·服务
  • 咨询方式
简介目录
Product Code: DMPH5469

Market Overview

The global cholecystitis treatment market size was valued at US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX% during the forecast period (2022-2029).

Cholecystitis is a gallbladder inflammation caused by gallstones obstructing the cystic duct. Inflammation of the gall bladder occurs when the tube responsible for fluid secretion is blocked. Tumors, significant sickness, and some infections are some of the other causes of cholecystitis. Acute cholecystitis and chronic cholecystitis are the two kinds of cholecystitis. Pain, fever, chills, nausea, and jaundice are among the symptoms experienced by the affected person.

Market Dynamics

The market for cholecystitis treatment has grown significantly over the last decade, owing to the increasing cases of gallstones and improved treatments practices. Furthermore, an increase in healthcare expenditure.

Increasing prevalence of gallbladder will drive the market growth

Global geriatric population growth, as well as an increase in gallstones cases, are only a few examples. The number and proportion of people aged 60 and up are growing. In 2019, there were one billion persons aged 60 and beyond. This figure is expected to rise to 1.4 billion by 2030 and 2.1 billion by 2050. This rise is occurring at an unprecedented rate, and it is likely to intensify in the future decades, particularly in emerging countries.

Moreover increasing prevalence of gallstones ,more than 85 percent of gallstones in developed countries are cholesterol stones. Gallstones affect around 20 million people in the United States (15 percent of the population). According to the Third National Health and Nutrition Examination Survey (NHANES III), Mexican-Americans have a higher prevalence than non-Hispanic whites, and non-Hispanic blacks have a lower prevalence. American Indians (particularly the Pima tribe of Arizona) had an unusually high incidence. Ultrasound studies in Europe revealed a prevalence of 9 - 21% and an incidence of 0.63/100 people per year.These factors are likely to boost the cholecystitis treatment market.

COVID-19 Impact Analysis

Pharmaceutical and biotech companies are helping governments worldwide to tackle the COVID-19 outbreak, from vaccine development to pharmaceutical supply chain planning. In the R&D pipeline, about 115 vaccine candidates and 155 chemicals are currently being developed. Furthermore, commonly used drugs, such as hydroxychloroquine, have seen a significant surge in demand for COVID-19 treatment. Manufacturers of COVID-19 management medications have a lot of opportunities due to the great need for these treatments, as many wealthy countries are running out of them. The pharmaceutical and biotechnology sectors are expected to grow dramatically due to increased demand for COVID-19 vaccines and treatment drugs. Manufacturers of COVID-19 management medications have a lot of opportunities due to the great demand for these treatments, as many wealthy countries are running out of them. The pharmaceutical and biotechnology sectors are expected to grow dramatically due to increased demand for COVID-19 vaccines and treatment drugs. As a result, the global cholecystitis treatment market has been severely damaged.

Segment Analysis

The tumor segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The cause segment is divided into gallstones, tumor, bile duct blockage ,infection,blood vesel problems.Tumor segment is expected to grow during the forecast period. A tumor is a solid mass of tissue formed when aberrant cells congregate. Tumors can damage the bones, the skin, the tissue, the organs, and the glands. Many benign tumors are not cancerous. However, they may still require therapy. Cancerous or malignant tumors can be fatal and necessitate cancer therapy. According to National Cancer Institute, the annual rate of new cancer cases (cancer incidence) is 442.4 per 100,000 men and women (from 2013 to 2017).Based on 2013-2017 deaths, the cancer death rate (cancer mortality) is 158.3 per 100,000 men and women per year.

Geographical Analysis

North America region holds the largest market share of the global cholecystitis treatment market

North America is expected to rise in the forecast period. According to studies, roughly 10-20 percent of Americans suffer with gallstones, which cause cholecystitis, hence the market for cholecystitis therapy is predicted to increase fast. Furthermore, market growth is fueled by rising awareness of disease symptoms as well as the presence of pipeline medications. Furthermore, market expansion is possible due to technology advancements in disease diagnostics and rising healthcare expenses.

North American region is developing novel treatment. Furthermore, rising death rates increased patient awareness of the availability of cholecystitis treatment. Advanced healthcare infrastructure is expected to drive the growth of the cholecystitis treatment market in North America.

Competitive Landscape

The cholecystitis treatment market is a highly competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Boston Scientific, Dornier MedTech GmbH, Fresenius Kabi, AuroMedics Pharmaceuticals, Sanofi, SUNUET Pharmaceuticals, Hetero Healthcare Limited, Takeda Pharmaceutical, Gilead Sciences Inc, Novartis, among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the cholecystitis treatment market globally. For instance, In March 2019, Dornier MedTech introduces Dornier OptiVision, a next-generation digital image processing technology for stone treatment and everyday endourology.

Fresenius Kabi

Overview:

Fresenius Kabi is a multinational healthcare firm that focuses on infusion, transfusion, and clinical nutrition drugs and technologies. Patients who are critically or chronically ill benefit from our products and services.

Product Portfolio:

Cefoperazone: Cefoperazone, a third-generation cephalosporin, is the antibacterial component of sulbactam/cefoperazone. It works against sensitive organisms during active multiplication by preventing the formation of cell wall mucopeptide. Except against Neisseriaceae and Acinetobacter, sulbactam has no effective antibacterial action. Because sulbactam interacts with several penicillin-binding proteins, sensitive strains are more vulnerable to sulbactam/cefoperazone than cefoperazone alone.

Table of Contents

1. Global Cholecystitis Treatment Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Cholecystitis Treatment Market-Market Definition and Overview

3. Global Cholecystitis Treatment Market- Executive Summary

  • 3.1. Market Snippet By Cause
  • 3.2. Market snippet By Treatment
  • 3.3. Market Snippet By End User
  • 3.4. Market Snippet by Region

4. Global Cholecystitis Treatment Market-Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing prevalence of cholecystitis
      • 4.1.1.2. Increasing sedentary lifestyle
    • 4.1.2. Restraints:
      • 4.1.2.1. Surgery is required in severe cases
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Cholecystitis Treatment Market- Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis

6. Global Cholecystitis Treatment Market- COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Cholecystitis Treatment Market- By Cause

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause Segment
    • 7.1.2. Market Attractiveness Index, By Cause Segment
  • 7.2. Gall Bladder Stones*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Tumor
  • 7.4. Bile Duct Blockage
  • 7.5. Microbial Infection
  • 7.6. Others

8. Global Cholecystitis Treatment Market- By Treatment

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 8.1.2. Market Attractiveness Index, By Treatment
  • 8.2. Medication *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. ERCP(Endoscopic Retrograde Cholangiopancreatography)

9. Global Cholecystitis Treatment Market- By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User Segment
  • 9.2. Hospital*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Gynecology Clinics
  • 9.4. Ambulatory Surgical Centers
  • 9.5. Others

10. Global Cholecystitis Treatment Market- By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cause
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Global Cholecystitis Treatment Market- Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Global Cholecystitis Treatment Market- Company Profiles

  • 12.1. Fresenius Kabi*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Dornier MedTech GmbH
  • 12.3. AuroMedics Pharmaceuticals
  • 12.4. Sanofi
  • 12.5. Sunuet Pharmaceuticals
  • 12.6. Hetero Healthcare
  • 12.7. Novartis
  • 12.8. Gilead Sciences Inc
  • 12.9. Takeda Pharmaceuticals
  • 12.10. Boston Scientific Corporation

LIST NOT EXHAUSTIVE

13. Global Cholecystitis Treatment Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us